Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

130.62 -0.14 (-0.11%)

Streaming Delayed Price Updated: 9:39 AM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Repligen Joins Elite List Of Stocks With 95-Plus Composite Rating ↗

June 18, 2021

The new score means Repligen is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.

Via Investor's Business Daily

Dow Jones Hits High As Metals, Miners, Fertilizers Thrive, But Growth Stocks Slump; Jobs Report Stunningly Weak ↗

May 07, 2021

The Dow hit highs but growth stocks slumped, despite a Friday bounce on weak jobs gains. Miners, metals, fertilizers thrived.

Via Investor's Business Daily

Repligen Corp (RGEN) Q1 2021 Earnings Call Transcript ↗

May 04, 2021

RGEN earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Repligen Earnings Double As Sales Growth Accelerates; RGEN Stock Nears Buy Point ↗

May 04, 2021

Repligen earnings shot up 113% in Q1 with sales growth accelerating to 88%. The biotech raised full-year guidance. RGEN stock rose, nearing a buy point.

Via Investor's Business Daily

Repligen: Q1 Earnings Insights ↗

May 04, 2021

Shares of Repligen (NASDAQ:RGEN) moved higher by 7.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 112.50% over...

Via Benzinga

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 04, 2021

Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7...

Via Benzinga

Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due ↗

April 28, 2021

A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue?

Via Investor's Business Daily

Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86 ↗

April 27, 2021

On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before.

Via Investor's Business Daily

Align Technology Nears Buy Point With Earnings Due ↗

April 21, 2021

Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28.

Via Investor's Business Daily

Earnings Scheduled For May 4, 2021 ↗

May 04, 2021

Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •...

Via Benzinga

Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark ↗

April 21, 2021

Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member.

Via Investor's Business Daily

Cancer Therapy Novocure Stock Flashes Renewed Technical Strength ↗

April 14, 2021

Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92.

Via Investor's Business Daily

10 Biggest Price Target Changes For Monday ↗

April 12, 2021

Canaccord Genuity raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $419 to $1071. Tesla shares rose 1.5% to $687.13 in pre-market trading. Keybanc lowered the price...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.